|
[1] Wang X, Jiang X. Mdm2 and mdmx partner to regulate p53. FEBS Letters, 2012, 586(10): 1390-1396.
[2] Phillips A, Teunisse A, Lam S, et al. Hdmx-l is expressed from a functional p53-responsive promoter in the first intron of the hdmx gene and participates in an autoregulatory feedback loop to control p53 activity. The Journal of Biological Chemistry, 2010, 285(38): 29111-29127.
[3] Jacob A G, Singh R K, Comiskey D F Jr, et al. Stress-induced alternative splice forms of mdm2 and mdmx modulate the p53-pathway in distinct ways. PloS One, 2014, 9(8): e104444.
[4] Jiang L, Kon N, Li T Y, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 2015, 520(7545): 57-62.
[5] Wade M, Li Y C, Wahl G M. Mdm2, mdmx and p53 in oncogenesis and cancer therapy. Nature Reviews Cancer, 2013, 13(2): 83-96.
[6] Hong B, van den Heuvel A P, Prabhu V V, et al. Targeting tumor suppressor p53 for cancer therapy: Strategies, challenges and opportunities. Current drug targets, 2014, 15(1): 80-89.
[7] Lane D, Levine A. P53 research: The past thirty years and the next thirty years. Cold Spring Harbor Perspectives in Biology, 2010, 2(12): a000893.
[8] Muller P A, Vousden K H. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer cell, 2014, 25(3): 304-317.
[9] Wade M, Wang Y V, Wahl G M. The p53 orchestra: Mdm2 and mdmx set the tone. Trends in Cell Biology, 2010, 20: 299-309.
[10] Berberich S J. Mdm2 and mdmx involvement in human cancer. Sub-cellular biochemistry, 2014, 85: 263-280.
[11] Lenos K, Jochemsen A G. Functions of mdmx in the modulation of the p53-response. Journal of Biomedicine & Biotechnology, 2011, 2011: 876173.
[12] Perry M E. The regulation of the p53-mediated stress response by mdm2 and mdm4. Cold Spring Harbor Perspectives in Biology, 2010, 2(1): a000968.
[13] Toledo F, Wahl G M. Mdm2 and mdm4: P53 regulators as targets in anticancer therapy. The International Journal of Biochemistry & Cell biology, 2007, 39(7-8): 1476-1482.
[14] Michaelis M, Rothweiler F, Barth S, et al. Adaptation of cancer cells from different entities to the mdm2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death & Disease, 2011, 2: e243.
[15] Wei S J, Joseph T, Sim A Y L, et al. In vitro selection of mutant hdm2 resistant to nutlin inhibition. PloS one, 2013, 8(4): e62564.
[16] Lane D P, Cheok C F, Lain S. P53-based cancer therapy. Cold Spring Harbor Perspectives in Biology, 2010, 2(9): a001222.
[17] Wang Y V, Leblanc M, Wade M, et al. Increased radioresistance and accelerated b cell lymphomas in mice with mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell, 2009, 16(1): 33-43.
[18] Macchiarulo A, Giacche N, Carotti A, et al. Expanding the horizon of chemotherapeutic targets: From mdm2 to mdmx (mdm4). Med Chem Comm, 2011, 2(6): 455-465.
[19] Popowicz G M, Domling A, Holak T A. The structure-based design of mdm2/mdmx-p53 inhibitors gets serious. Angewandte Chemie, 2011, 50(12): 2680-2688.
[20] Chen G X, Zhang S, He X H, et al. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets and therapy, 2014, 7: 1901-1909.
[21] Roth J A. Adenovirus p53 gene therapy. Expert opinion on biological therapy, 2006, 6(1): 55-61.
[22] Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nature biotechnology, 2004, 22(1): 3-4.
[23] Issaeva N, Bozko P, Enge M, et al. Small molecule rita binds to p53, blocks p53-hdm-2 interaction and activates p53 function in tumors. Nature Medicine, 2004, 10(12): 1321-1328.
[24] Zhang Q, Zeng S X, Lu H. Targeting p53-mdm2-mdmx loop for cancer therapy. Sub-cellular Biochemistry, 2014, 85: 281-319.
[25] Khoo K H, Verma C S, Lane D P. Drugging the p53 pathway: Understanding the route to clinical efficacy. Nature reviews Drug Discovery, 2014, 13(3): 217-236.
[26] Vassilev L T, Vu B T, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of mdm2. Science, 2004, 303(5659): 844-848.
[27] Ray-Coquard I, Blay J Y, Italiano A, et al. Effect of the mdm2 antagonist rg7112 on the p53 pathway in patients with mdm2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study. The Lancet Oncology, 2012, 13(11): 1133-1140.
[28] Ding K, Lu Y, Nikolovska-Coleska Z, et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the mdm2-p53 interaction. Journal of Medicinal Chemistry, 2006, 49(12): 3432-3435.
[29] Parks D J, LaFrance L V, Calvo R R, et al. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the hdm2-p53 protein-protein interaction through structure-based drug design. Bioorganic & Medicinal Chemistry Letters, 2006, 16(12): 3310-3314.
[30] Rothweiler U, Czarna A, Krajewski M, et al. Isoquinolin-1-one inhibitors of the mdm2-p53 interaction. Chem Med Chem, 2008, 3(7): 1118-1128.
[31] Rew Y, Sun D, Gonzalez-Lopez De Turiso F, et al. Structure-based design of novel inhibitors of the mdm2-p53 interaction. Journal of Medicinal Chemistry, 2012, 55(11): 4936-4954.
[32] Zhuang C, Miao Z, Zhu L, et al. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-mdm2 protein-protein interaction. Journal of Medicinal Chemistry, 2012, 55(22): 9630-9642.
[33] Wang W, Shangguan S, Qiu N, et al. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-mdm2 interaction. Part 1. Bioorganic & Medicinal Chemistry, 2013, 21(11): 2879-2885.
[34] Graves B, Thompson T, Xia M, et al. Activation of the p53 pathway by small-molecule-induced mdm2 and mdmx dimerization. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(29): 11788-11793.
[35] Pazgier M, Liu M, Zou G, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with mdm2 and mdmx. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(12): 4665-4670.
[36] Sanchez M C, Renshaw J G, Davies G, et al. Mdm4 binds ligands via a mechanism in which disordered regions become structured. FEBS Letters, 2010, 584(14): 3035-3041.
[37] Su Z D, Royappa G, Duda D, et al. Structural mechanism of the p53-binding domains of mdm2/mdmx with ligands. Symposium on Biomolecular Structure, Dynamics & Function, 2012, 1(1): 2.
[38] Popowicz G M, Czarna A, Wolf S, et al. Structures of low molecular weight inhibitors bound to mdmx and mdm2 reveal new approaches for p53-mdmx/mdm2 antagonist drug discovery. Cell Cycle, 2010, 9(6): 1104-1111.
[39] Qin L, Yang F, Zhou C, et al. Efficient reactivation of p53 in cancer cells by a dual mdmx/mdm2 inhibitor. Journal of the American Chemical Society, 2014, 136(52): 18023-18033.
[40] Cragg G M, Newman D J. Natural products: A continuing source of novel drug leads. Biochimica et Biophysica Acta, 2013, 1830(6): 3670-3695.
[41] Molinski T F. All natural: The renaissance of natural products chemistry. The Journal of Organic Chemistry, 2014, 79(15): 6765.
[42] Molinski T F, Dalisay D S, Lievens S L, et al. Drug development from marine natural products. Nature Reviews Drug discovery, 2009, 8(1): 69-85.
[43] Giddings L A, Newman D J. Microbial natural products: Molecular blueprints for antitumor drugs. Journal of Industrial Microbiology & Biotechnology, 2013, 40(11): 1181-1210.
[44] Li J W, Vederas J C. Drug discovery and natural products: End of an era or an endless frontier? Science, 2009, 325(5937): 161-165.
[45] Newman D J, Cragg G M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal of Natural Products, 2012, 75(3): 311-335.
[46] Newman D, Cragg G. Natural products in medicinal chemistry. Bioorganic & Medicinal Chemistry, 2009, 17(6): 2120.
|
